|1.||Kaneko, S: 3 articles (08/2000 - 04/2000)|
|2.||Otani, K: 3 articles (08/2000 - 04/2000)|
|3.||Ono, S: 3 articles (08/2000 - 04/2000)|
|4.||Nagashima, U: 3 articles (08/2000 - 04/2000)|
|5.||Mihara, K: 3 articles (08/2000 - 04/2000)|
|6.||Kondo, T: 3 articles (08/2000 - 04/2000)|
|7.||Mihara, Kazuo: 2 articles (04/2007 - 02/2002)|
|8.||Yasui-Furukori, Norio: 2 articles (04/2007 - 02/2002)|
|9.||Kondo, Tsuyoshi: 2 articles (04/2007 - 02/2002)|
|10.||Yasui, N: 2 articles (08/2000 - 04/2000)|
09/04/1998 - "Nemonapride induced catalepsy in both cross-legged position and bar tests at low, but not at high doses. "
09/04/1998 - "The present data indicate that the 5-HT1A receptor agonist properties of nemonapride attenuate its ability to induce catalepsy at higher doses, and suggest further that tonic 5-HT1A receptor activation may modulate neuroleptic-induced catalepsy."
06/01/1997 - "After coadministration of SCH23390 and nemonapride, catalepsy was stronger than sum of the values predicted by single administration of each drug, and it was intensified synergistically. "
02/01/1987 - "Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats."
03/01/2003 - "Effective doses of terguride had no systematic effect on motor activity or muscle rigidity, whereas effective doses of nemonapride virtually eliminated motor activity and induced severe catalepsy. "
|3.||Schizophrenia (Dementia Praecox)
09/04/1998 - "This method is applicable to drug level monitoring in the plasma of schizophrenia patients treated with nemonapride and to the study of pharmacokinetics."
08/01/2000 - "These findings suggest that nemonapride has a broad therapeutic spectrum in the treatment of acute schizophrenia. "
02/01/1997 - "Nemonapride for the treatment of schizophrenia."
12/01/1996 - "Effects of nemonapride on positive and negative symptoms of schizophrenia."
04/01/2007 - "The subjects consisted of 49 acutely exacerbated inpatients with schizophrenia treated with bromperidol (30 cases, 6-18 mg/day) or nemonapride (19 cases, 18 mg/day) for 3 weeks. "
06/13/1996 - "In contrast, during the recirculation periods, [3H]nemonapride and [3H]mazindol binding was mostly unaffected in this region which was the most vulnerable to ischemia. "
11/01/1997 - "The parietal cortex and thalamus also exhibited no significant changes in [3H]SCH23390, [3H]nemonapride and [3H]mazindol binding after ischemia. "
06/13/1996 - "The frontal cortex, where ischemic neuronal damage was mild, also showed no significant changes in [3H]SCH23390, [3H]nemonapride and [3H]mazindol binding after ischemia. "
|9.||Antipsychotic Agents (Antipsychotics)